Background Patient attitudes to and satisfaction with their treatment are associated with improved adherence. There is a paucity of data on patient drug attitudes and preference to oral compared to long-acting injectable (LAI) antipsychotic treatment. Aim To describe patients attitudes and preferences towards oral versus LAI antipsychotic formulations and explore factors associated with their drug attitudes. Setting Two psychiatric hospitals in KwaZulu-Natal, South Africa. Method A cross–sectional survey of 140 adult outpatients with schizophrenia spectrum disorders receiving LAI with or without oral antipsychotics (a total of 70) were compared to patients receiving oral antipsychotics only (N = 70). A sociodemographic-clinical questionnaire, chart review and the Drug Attitude Inventory scale (DAI–30) were used. Results Of the 140 participants, 98 (70%) preferred the medication formulation currently prescribed, and 132 (94.3%) reported a positive drug attitude towards their antipsychotic medication. The adjusted regression analysis indicated that study participants who were currently on a formulation that matched their preference scored better on the DAI-30 than individuals with a mismatch in use and preference (p < 0.04). In terms of covariates, we found, on one hand, that study participants who are divorced (compared to single) with schizophrenia diagnosis (compared to other psychotic or schizoaffective disorder) are more likely to have lower score on DAI-30. On the other hand, we found that study participants with a higher household income and longer duration of the psychotic illness were associated with greater DAI-30 score. Conclusion The majority of participants preferred their current oral and LAI formulation. Drug attitude was influenced by several factors, including matched medication use. Focused psychoeducation should be considered for newly diagnosed, lower socio-economic groups and patients with non-affective psychosis to improve drug attitude.

中文翻译：

---

南非夸祖鲁-纳塔尔省精神病患者对口服和长效注射抗精神病药的态度和偏好。

背景 患者对其治疗的态度和满意度与依从性的提高有关。与长效注射 (LAI) 抗精神病药物治疗相比，关于患者药物态度和对口服药物的偏好的数据很少。目的 描述患者对口服与 LAI 抗精神病制剂的态度和偏好，并探索与他们的药物态度相关的因素。设置 南非夸祖鲁-纳塔尔省的两家精神病院。方法 对 140 名接受 LAI 联合或不联合口服抗精神病药（共 70 名）与仅接受口服抗精神病药的患者（N = 70）进行横断面调查。使用了社会人口学临床问卷、图表审查和药物态度量表（DAI-30）。结果 在 140 名参与者中，98 人 (70%) 更喜欢目前处方的药物配方，132 人 (94.3%) 报告对他们的抗精神病药物持积极态度。调整后的回归分析表明，目前使用与其偏好相匹配的配方的研究参与者在 DAI-30 上的得分高于使用和偏好不匹配的个体（p < 0.04）。在协变量方面，我们发现，一方面，被诊断为精神分裂症（与其他精神病或分裂情感障碍相比）离婚（与单身相比）的研究参与者更有可能在 DAI-30 上得分较低。另一方面，我们发现家庭收入较高和精神病病程较长的研究参与者与较高的 DAI-30 评分相关。结论 大多数参与者更喜欢他们目前的口服和 LAI 制剂。药物态度受几个因素的影响，包括匹配的药物使用。对新诊断、社会经济地位较低的群体和非情感性精神病患者应考虑进行针对性的心理教育，以改善药物态度。